M
M. Shan
Publications - 13
Citations - 6480
M. Shan is an academic researcher. The author has contributed to research in topics: Sorafenib & Cancer. The author has an hindex of 9, co-authored 9 publications receiving 6217 citations.
Papers
More filters
Journal ArticleDOI
Sorafenib in advanced clear-cell renal-cell carcinoma.
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Siebels,Sylvie Negrier,Christine Chevreau,Ewa Solska,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Scott Freeman,Brian Schwartz,M. Shan,Ronit Simantov,Ronald M. Bukowski +18 more
TL;DR: As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects.
Journal ArticleDOI
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Bernard Escudier,Tim Eisen,Walter M. Stadler,Cezary Szczylik,Stéphane Oudard,Michael Staehler,Sylvie Negrier,Christine Chevreau,Apurva A. Desai,Frederic Rolland,Tomasz Demkow,Thomas E. Hutson,Martin Gore,Sibyl Anderson,Gloria Hofilena,M. Shan,Carol Peña,Chetan Lathia,Ronald M. Bukowski +18 more
TL;DR: Although an OS benefit was not seen on a primary intent-to-treat analysis, results of a secondary OS analysis censoring placebo patients demonstrated a survival advantage for those receiving sorafenib, suggesting an important cross-over effect.
Journal ArticleDOI
Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)
Bernard Escudier,C. Szczylik,Timothy Eisen,Walter M. Stadler,Brian Schwartz,M. Shan,Ronald M. Bukowski +6 more
TL;DR: This Phase III, double-blind trial to assess overall survival (OS) in pts with confirmed advanced clear-cell RCC randomized to BAY vs best supportive care (BSC) and results of a planned analysis on the secondary endpoint, progression free survival (PFS) will be presented in this report.
Journal ArticleDOI
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
TL;DR: VEGF, CAIX, TIMP-1, and Ras p21 levels were prognostic for survival in RCC patients, and TIMp-1 has emerged as being independently prognostic.
Journal ArticleDOI
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
Ronald M. Bukowski,Timothy Eisen,C. Szczylik,Walter M. Stadler,Ronit Simantov,M. Shan,J. Elting,Carol Peña,Bernard Escudier +8 more
TL;DR: Final OS differences did not reach prespecified O’Brien-Fleming statistical boundaries and are reported.